ONCY

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Oncolytics Biotech Inc

NASDAQ | ONCY

1.11

USD

$0.00

(

0.00%

)

At Close (As of Oct 21, 2025)

$119.47M

Market Cap

-

P/E Ratio

-0.25

EPS

$1.51

52 Week High

$0.32

52 Week Low

HEALTHCARE

Sector

ONCY Chart

Recent Chart
Price Action

ONCY Technicals

Tags:

ONCY Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (CAD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$35M
Selling General And Administrative $13M
Research And Development $22M
Operating Expenses $35M
Investment Income Net -
Net Interest Income $1.2M
Interest Income $1.2M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $102K
Income Before Tax -$32M
Income Tax Expense $130K
Interest And Debt Expense -
Net Income From Continuing Operations -$32M
Comprehensive Income Net Of Tax -
Ebit -$35M
Ebitda -$35M
Net Income -$32M

Revenue & Profitability

Earnings Performance

ONCY Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (CAD)
Total Assets $20M
Total Current Assets $19M
Cash And Cash Equivalents At Carrying Value $16M
Cash And Short Term Investments $16M
Inventory -
Current Net Receivables $68K
Total Non Current Assets $1.3M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $2.9M
Other Non Current Assets -
Total Liabilities $14M
Total Current Liabilities $6.7M
Current Accounts Payable $1.1M
Deferred Revenue -
Current Debt -
Short Term Debt $277K
Total Non Current Liabilities $7.5M
Capital Lease Obligations $1.1M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.1M
Other Current Liabilities $5.3M
Other Non Current Liabilities -
Total Shareholder Equity $6M
Treasury Stock -
Retained Earnings -$478M
Common Stock $438M
Common Stock Shares Outstanding $76M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (CAD)
Operating Cashflow -$27M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $424K
Capital Expenditures $239K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$239K
Cashflow From Financing $6.6M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$32M

yearly Income Statement (As of Dec 31, 2024)

Field Value (CAD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$35M
Selling General And Administrative $13M
Research And Development $22M
Operating Expenses $35M
Investment Income Net -
Net Interest Income $1.2M
Interest Income $1.2M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $102K
Income Before Tax -$32M
Income Tax Expense $130K
Interest And Debt Expense -
Net Income From Continuing Operations -$32M
Comprehensive Income Net Of Tax -
Ebit -$35M
Ebitda -$35M
Net Income -$32M

ONCY News

ONCY Profile

Oncolytics Biotech Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Oncolytics Biotech Inc. (ONCY) is a Calgary-based clinical-stage biopharmaceutical company focused on pioneering oncolytic virus therapies for cancer treatment. Its leading candidate, pelareorep, uniquely targets cancer cells while enhancing the body’s immune response against tumors. With a robust pipeline and ongoing clinical trials, Oncolytics aims to deliver innovative solutions for patients with a range of cancers. The company leverages strategic collaborations and a strong research background, positioning itself as a key player in the evolving oncology market.

BYND
+146.25%
$3.62
YDKG
+28.66%
$0.05
VHAI
0.00%
$0.00
YYAI
-19.38%
$0.08
F
+4.83%
$12.57
VSEE
+73.97%
$0.84
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
GDXD
+29.73%
$0.86
BITF
-0.59%
$4.98
RANI
+38.22%
$3.11
BURU
-15.23%
$0.28
ADAP
-17.79%
$0.04
NVDA
-0.74%
$181.27
T
-0.26%
$26.03
PLUG
-9.26%
$3.08
NVTS
+16.64%
$17.10
GPUS
+24.21%
$0.39
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
DNN
-6.99%
$2.72
RGTI
-9.03%
$39.39
AXDX
-61.36%
$0.03
BOF
+34.36%
$2.81
CLF
-17.27%
$13.38
BTG
-9.47%
$5.15
INTC
+0.02%
$38.11
DVLT
0.00%
$2.41
WBD
+11.98%
$20.51
IBIO
+24.30%
$1.11
GSIT
-15.34%
$10.98
TLRY
-5.41%
$1.48
SOFI
+0.24%
$28.75
JOBY
-8.72%
$15.91
ABEV
-2.42%
$2.21
RIG
+0.45%
$3.30
TSLA
-1.07%
$442.60
RXRX
-9.74%
$6.02
ETHD
-0.93%
$3.71
AMZN
+2.56%
$222.03
AMD
-1.05%
$238.03
RF
+1.10%
$24.32
EOSE
+7.19%
$16.09
IONZ
+0.98%
$4.08
RR
+1.25%
$5.63
LAES
-8.46%
$5.93
SOUN
-4.35%
$18.23
BTBT
-8.29%
$3.87
NEHC
+23.95%
$5.64
QUBT
-9.08%
$15.70
ACHR
-5.30%
$11.34
QBTS
-6.36%
$32.21
RMBL
+60.50%
$3.21
HAL
+11.53%
$25.23
MARA
-3.18%
$20.07
IREN
-6.70%
$55.25
DCGO
+24.16%
$1.49
BBD
-2.21%
$3.30
ADD
-25.47%
$0.05
AAL
+1.47%
$12.35
GOOGL
-1.92%
$251.60
GM
+14.87%
$66.62
DFLI
-3.96%
$1.21
AAPL
+0.38%
$263.26
CLSK
-7.62%
$18.84
NIO
-3.61%
$6.80
SRM
+53.27%
$10.30
VALE
-0.92%
$11.29
BMNR
-3.45%
$51.94
YGMZ
-77.05%
$0.21
AMC
+3.61%
$2.87
NOK
-1.92%
$5.60
PFE
+0.38%
$24.78
PLTR
+1.93%
$181.59
PBR
-1.02%
$11.57
GRAB
+0.53%
$5.67
HIMS
+3.17%
$51.36
SMR
-13.23%
$38.36
VZ
-1.23%
$40.29
CUTR
-10.19%
$0.09
WLGS
-5.57%
$0.04
CIFR
-11.39%
$17.64
KO
+3.93%
$71.13
GGB
-0.73%
$3.38
CJET
-20.74%
$0.08
GOOG
-2.20%
$251.34
SNAP
+1.22%
$7.82
ETWO
0.00%
$3.30
APLD
-9.35%
$32.54
BULL
-2.96%
$11.14
IONQ
-0.71%
$59.51
PM
-3.82%
$152.02
RGTZ
+15.41%
$15.65
AG
-11.17%
$12.75
RIVN
+1.56%
$13.28
ONDS
-7.97%
$7.15
WTO
-1.08%
$0.06
UAMY
-7.89%
$12.37
CDE
-16.13%
$18.47
AFMD
-34.94%
$0.18
BYND
+146.25%
$3.62
YDKG
+28.66%
$0.05
VHAI
0.00%
$0.00
YYAI
-19.38%
$0.08
F
+4.83%
$12.57
VSEE
+73.97%
$0.84
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
GDXD
+29.73%
$0.86
BITF
-0.59%
$4.98
RANI
+38.22%
$3.11
BURU
-15.23%
$0.28
ADAP
-17.79%
$0.04
NVDA
-0.74%
$181.27
T
-0.26%
$26.03
PLUG
-9.26%
$3.08
NVTS
+16.64%
$17.10
GPUS
+24.21%
$0.39
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
DNN
-6.99%
$2.72
RGTI
-9.03%
$39.39
AXDX
-61.36%
$0.03
BOF
+34.36%
$2.81
CLF
-17.27%
$13.38
BTG
-9.47%
$5.15
INTC
+0.02%
$38.11
DVLT
0.00%
$2.41
WBD
+11.98%
$20.51
IBIO
+24.30%
$1.11
GSIT
-15.34%
$10.98
TLRY
-5.41%
$1.48
SOFI
+0.24%
$28.75
JOBY
-8.72%
$15.91
ABEV
-2.42%
$2.21
RIG
+0.45%
$3.30
TSLA
-1.07%
$442.60
RXRX
-9.74%
$6.02
ETHD
-0.93%
$3.71
AMZN
+2.56%
$222.03
AMD
-1.05%
$238.03
RF
+1.10%
$24.32
EOSE
+7.19%
$16.09
IONZ
+0.98%
$4.08
RR
+1.25%
$5.63
LAES
-8.46%
$5.93
SOUN
-4.35%
$18.23
BTBT
-8.29%
$3.87
NEHC
+23.95%
$5.64
QUBT
-9.08%
$15.70
ACHR
-5.30%
$11.34
QBTS
-6.36%
$32.21
RMBL
+60.50%
$3.21
HAL
+11.53%
$25.23
MARA
-3.18%
$20.07
IREN
-6.70%
$55.25
DCGO
+24.16%
$1.49
BBD
-2.21%
$3.30
ADD
-25.47%
$0.05
AAL
+1.47%
$12.35
GOOGL
-1.92%
$251.60
GM
+14.87%
$66.62
DFLI
-3.96%
$1.21
AAPL
+0.38%
$263.26
CLSK
-7.62%
$18.84
NIO
-3.61%
$6.80
SRM
+53.27%
$10.30
VALE
-0.92%
$11.29
BMNR
-3.45%
$51.94
YGMZ
-77.05%
$0.21
AMC
+3.61%
$2.87
NOK
-1.92%
$5.60
PFE
+0.38%
$24.78
PLTR
+1.93%
$181.59
PBR
-1.02%
$11.57
GRAB
+0.53%
$5.67
HIMS
+3.17%
$51.36
SMR
-13.23%
$38.36
VZ
-1.23%
$40.29
CUTR
-10.19%
$0.09
WLGS
-5.57%
$0.04
CIFR
-11.39%
$17.64
KO
+3.93%
$71.13
GGB
-0.73%
$3.38
CJET
-20.74%
$0.08
GOOG
-2.20%
$251.34
SNAP
+1.22%
$7.82
ETWO
0.00%
$3.30
APLD
-9.35%
$32.54
BULL
-2.96%
$11.14
IONQ
-0.71%
$59.51
PM
-3.82%
$152.02
RGTZ
+15.41%
$15.65
AG
-11.17%
$12.75
RIVN
+1.56%
$13.28
ONDS
-7.97%
$7.15
WTO
-1.08%
$0.06
UAMY
-7.89%
$12.37
CDE
-16.13%
$18.47
AFMD
-34.94%
$0.18
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.